EPO Dosing Questions Left Unanswered; More Data, More Meetings Needed

Amgen does not currently have enough data to characterize the relationship between targeted hemoglobin levels in patients receiving erythropoiesis-stimulating agents and clinical outcomes in the oncologic setting